Nicotinamide Phosphoribosyltransferase Deficiency Potentiates the Anti-proliferative Activity of Methotrexate through Enhanced Depletion of Intracellular ATP

Rakesh K. Singh, Leon van Haandel, Daniel P. Heruth, Shui Q. Ye, J. Steven Leeder, Mara L. Becker, Ryan S. Funk

Department of Pharmacy Practice, The University of Kansas Medical Center, Kansas City, KS 66160 (RKS and RSF)
Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Children’s Mercy Kansas City, Kansas City, MO 64108 (LVH, JSL, and MLB)
Division of Rheumatology, Children’s Mercy Kansas City, Kansas City, MO 64108 (MLB)
Division of Experimental and Translational Genetics, Children’s Mercy Kansas City, Kansas City, MO 64108 (DPH and SQY)
Department of Pharmacology, Toxicology, and Therapeutics, The University of Kansas Medical Center, Kansas City, KS 66160 (JSL and RSF)
Department of Biomedical and Health Informatics, University of Missouri Kansas City School of Medicine, Kansas City, Kansas City, MO 64108 (SQY)
Running title: NAMPT Deficiency Potentiates ATP Depletion by Methotrexate

Corresponding Author: Ryan S. Funk, PharmD, PhD, The University of Kansas Medical Center, 3901 Rainbow Blvd, MS 4047, Rm 6013, Kansas City, KS 66160; Phone: 913-945-6904; Fax: 913-945-2355; E-mail: ryanfunk@kumc.edu

Number of text pages: 17
Number of tables: 0
Number of figures: 9
Number and references: 43
Number of words in the Abstract: 250
Number of words in the Introduction: 727
Number of words in the Discussion: 1523

Non standard abbreviations: AICART, aminoimidazole carboxamide ribonucleotide transformylase; DMARD, Disease-modifying anti-rheumatic drug; JIA, Juvenile idiopathic arthritis; MTX, Methotrexate; NAMPT, Nicotinamide phosphoribosyltransferase; PBEF, Pre-B cell colony enhancing factor; PBMCs, peripheral blood mononuclear cells; phytohemagglutinin, PHA; RA, Rheumatoid arthritis.

Section Assignment Recommendation:
Inflammation, Immunopharmacology, and Asthma
Abstract

Lower plasma nicotinamide phosphoribosyltransferase (NAMPT) levels are associated with improved response to methotrexate (MTX) in patients with juvenile idiopathic arthritis (JIA). Cell-based studies confirmed that reduced cellular NAMPT activity potentiates the pharmacologic activity of MTX, however the mechanism of this interaction has yet to be defined. Therefore, in this study we investigate the mechanism of enhanced pharmacologic activity of MTX in NAMPT-deficient A549 cells. The siRNA-based silencing of NAMPT expression resulted in a greater than three-fold increase in the sensitivity to MTX (p<0.005) that was completely reversed by supplementation with folinic acid. Despite a 68% reduction in cellular NAD levels in NAMPT-deficient cells, no change in expression or activity of dihydrofolate reductase was observed and uptake of MTX was not found to be significantly altered. MTX was not found to potentiate the depletion of cellular NAD levels, but NAMPT-deficient cells had significant elevations in levels of intermediates of de novo purine biosynthesis and were 4-fold more sensitive to depletion of ATP by MTX (p<0.005). Supplementation with hypoxanthine and thymidine completely reversed the anti-proliferative activity of MTX in NAMPT-deficient cells, and corresponded to repletion of the cellular ATP pool without any effect on NAD levels. Together, these findings demonstrate that increased MTX activity with decreased NAMPT expression is dependent on the anti-folate activity of MTX, and is driven by enhanced sensitivity to the ATP-depleting effects of MTX. For the first time, these findings provide mechanistic details to explain the increase in pharmacological activity of MTX under conditions of reduced NAMPT activity.
Introduction

In a previous study by our group, lower plasma concentrations of nicotinamide phosphoribosyltransferase (NAMPT) were found to be associated with improved therapeutic response to the disease-modifying anti-rheumatic drug (DMARD) methotrexate (MTX) in patients with juvenile idiopathic arthritis (JIA) (Funk et al., 2016). Subsequent cell-based studies using siRNA-based gene silencing or the chemical inhibitor of NAMPT, known as FK-866 or daporinad, demonstrated that reductions in cellular NAMPT activity resulted in a marked increase in sensitivity to the anti-proliferative activity of MTX (Funk et al., 2016). Although these findings demonstrated that variation in NAMPT activity is associated with variation in MTX response, both in vivo and in vitro, the mechanism of this interaction remains poorly understood and is the focus of this work.

MTX is an anti-folate and the cornerstone of DMARD therapy in the treatment of autoimmune arthritis, including JIA and rheumatoid arthritis (RA). MTX is a potent inhibitor of dihydrofolate reductase (DHFR) and is metabolized intracellularly to form a series of pharmacologically active polyglutamated metabolites that function as direct inhibitors of several folate-dependent enzymes (Fairbanks et al., 1999; Kremer, 2004). Through inhibition of the folate-dependent biochemical pathways, MTX causes the inhibition of various downstream one-carbon transfer reactions, including nucleotide and methionine biosynthesis, which are believed to be responsible for its pharmacological activity in the treatment of autoimmune arthritis (Piper et al., 1983; Smolenska et al., 1999). Therapeutic response to MTX in the treatment of arthritis continues to be variable with approximately one in three patients failing to adequately respond to therapy, and has resulted in an effort to understand the mechanistic basis for the observed variation in drug response (Ravelli et al., 1998; Bulatovic et al., 2011). Therefore, our
observation that variation in NAMPT activity is associated with variation in the pharmacological activity of MTX warrants further investigation to understand the mechanism for this interaction.

Nicotinamide phosphoribosyltransferase (NAMPT), also known as pre-B cell colony enhancing factor (PBEF) or visfatin, functions as the rate-limiting enzyme in the mammalian salvage pathway for intracellular nicotinamide adenine dinucleotide (NAD) biosynthesis (Samal et al., 1994; Friebe et al., 2011). However, NAMPT is also secreted from cells through an undefined pathway and is found at relatively high concentrations in the plasma, with one study reporting concentrations of 7.2±0.9 ng/ml in normal healthy adults (Liakos et al., 2016). Although an extracellular receptor for NAMPT is yet to be definitively identified, it is commonly referred to as an adipocytokine and when supplied in its exogenous form has been demonstrated to be important in the regulation of cellular metabolism, inflammation, and immune function (Otero et al., 2006; Moschen et al., 2010; Mirfeizi et al., 2014). NAMPT has been investigated as a plasma biomarker of inflammation and more recently as a potential drug target in the treatment of rheumatoid arthritis (Rongvaux et al., 2008; Evans et al., 2011; Presumey et al., 2013). Inhibition of NAMPT in the collagen-induced arthritis mouse model has demonstrated efficacy similar to that of the anti-TNFα biologic etanercept, and has been primarily attributed to the inhibition of intracellular NAD biosynthesis in inflammatory cells (Busso et al., 2008; Evans et al., 2011).

Based on our understanding of the biological function of NAMPT, it is reasonable to hypothesize that the enhanced sensitivity to MTX observed following inhibition of NAMPT likely results from the depletion of the cellular NAD pool. Previous work investigating the NAMPT inhibitor GMX1777, also known as teglarinad chloride, demonstrated that silencing of folate-related genes enhances the cytotoxicity of GMX1777 (Chan et al., 2014). Similarly, they
found that the anti-folate drug pemetrexed promotes GMX1777 cytotoxicity through the synergistic depletion of cellular NAD resulting from activation of the NAD-consuming DNA repair enzyme poly (ADP-ribose) polymerase-1 (PARP-1) by pemetrexed (Chan et al., 2014). However, in the case of non-cytotoxic reduction of cellular NAD through siRNA-based gene silencing of NAMPT it remains unclear how reductions in NAMPT activity promotes the anti-proliferative activity of MTX. In this work, we hypothesize that partial depletion of cellular NAD through reduced expression of NAMPT increases the anti-proliferative effects of MTX mediated through inhibition of nucleotide biosynthesis and results in the synergistic depletion of cellular ATP.

Here, we investigate the mechanism of increased pharmacological activity of MTX in NAMPT-deficient cells through targeted silencing of NAMPT. Through measurement and supplementation of key metabolic pathways we derive the biochemical basis through which reduced enzymatic activity of NAMPT promotes the pharmacologic activity of MTX.

Materials and Methods

**Cell culture.** A549 human lung carcinoma cells (catalog no. CCL-185) were purchased from ATCC (Manassas, VA) and foreskin fibroblasts (AG07095) were provided by Coriell (Camden, NJ). Cells were grown in DMEM (catalog no. 11995-065) supplemented with 10% fetal bovine serum (catalog no. 03-600-511), 100 U/mL penicillin, and 100 U/mL streptomycin (ThermoFisher Scientific, Waltham, MA). Cells were maintained at 37°C in a 5% CO₂ controlled incubator and were passaged every 3 to 4 days at ~80% confluency.

**Peripheral blood mononuclear cells.** Peripheral blood mononuclear cells (PBMCs) were isolated using density gradient separation (Ficoll-Paque Plus, GE Healthcare, Piscataway,
NJ, USA). Blood was diluted with PBS in equal volume, 4 ml of diluted blood was carefully layered on the top of 3 ml Ficoll in a centrifuge tube to minimize mixing. Samples were centrifuged at 20°C for 30 minutes at 400 x g. PBMCs were carefully extracted from the centrifuge tube and diluted with PBS in 1:3 ratio and centrifuged at 100 x g for 10 min for washing. Washing was repeated one more time. PBMCs were suspended in RPMI-1640 media supplemented with 10% FBS and incubated for 24 hours to allow monocytes to attach. The next day, the lymphocytes remaining in suspension were seeded at the density of 25x10^3 cells/well in 96 well plate with or without 2% v/v phytohemagglutinin (PHA) and treated with DMSO or 10 nM MTX for the first 48 hours and then with 0.1 nM FK-866 for next 72 hours. Cell viability was assessed using the resazurin reduction assay described below.

**Cell Viability.** For viability studies, cells were seeded at the density of 5x10^3 cells per well in 96 well clear bottom black plates (Corning Inc., Corning, NY). With each well containing 100 μL of growth medium, 20 μL of 0.16 mg/mL rezasurin was added and incubated for 4 hours at 37 °C and 5% CO2. The plate was protected from light and allowed to cool to room temperature for 10 minutes prior to reading. Fluorescence signal was measured for each sample using a BioTek Cytation 3 as described previously (Funk et al., 2016). Protein content was quantified using the Micro BCA Protein Assay Kit (ThermoFisher Scientific, Waltham, MA).

**NAMPT inhibition and drug treatment.** Transfections were performed as described previously (Funk et al., 2016). In brief, in each well of a six-well plate, 250 pmoles of siRNA and 5 μL of Lipofectamine 2000 (ThermoFisher Scientific, Waltham, MA) each in 250 μL of Opti-MEM reduced serum media (ThermoFisher Scientific, Waltham, MA) were mixed at room temperature for 5 minutes before adding to 1.5 mL of antibiotic-free growth media containing 2.5x10^5 cells. Volumes and densities were scaled to 5x10^3 cells per well for 96-well plate
assays. After 24 hours, transfection media was replaced with either normal growth media or normal growth media containing various concentrations of methotrexate (MTX), and maintained for an additional 96 hours under normal culture conditions prior to analysis. For rescue experiments, cells were treated with either MTX alone or MTX with rescue drugs.

**Western Blot.** Cell lysates were prepared in RIPA buffer (ThermoFisher Scientific, Waltham, MA) supplemented with protease and phosphatase inhibitors (ThermoFisher Scientific, Waltham, MA). Equal amounts of protein were subjected to SDS-PAGE then transferred to polyvinylidene membrane (EMD Millipore, Billerica, MA). The membrane was blocked with 5% non-fat dry milk in phosphate-buffered saline containing 0.1% Tween 20 (TBS-T) at room temperature for 1 hour and then incubated at 4°C overnight with primary antibody. Primary antibodies were rabbit anti-NAMPT (1:4000) (in house generated), mouse anti-DHFR (1:750)( R&D Systems, Minneapolis, MN) mouse anti-Poly ADP-ribose clone 10H (1:1000) (Sigma-Aldrich, St. Louis, MO), PARP (1:1000) (Cell signaling, Danvers, MA), GAPDH (1:10,000)(Santa Cruz biotechnology, Dallas, TX). After washing three times for 10 minutes with TBS-T, the membrane was incubated with horseradish-peroxidase-linked goat anti Rabbit or Mouse secondary antibody (Santa Cruz Biotechnology, Dallas, TX) at room temperature for 1 hour. The blots were then visualized with the Pierce ECL Western blot detection reagent (ThermoFisher Scientific, Waltham, MA). Band density on Western blot images was used as a measure of assayed protein level.

**RNA Isolation, Reverse Transcription, and Real Time PCR Analysis.** Total RNA was isolated from A549 cells transfected with either control or NAMPT siRNA as described in the NAMPT inhibition section with TRIZol® reagent (Invitrogen). One microgram RNA was used for reverse complementation using iScriptTM cDNA synthesis kit, following the manufacturer's
protocol (Bio-Rad). Real time PCR was performed with the NAMPT primers sense 5’-tccacccaacacaagcaagt -3’; antisense 5’-ttcctctgggaatgacaaagccct -3’ using the CFX384TM real time PCR system (Bio-Rad) (Chavan et al., 2015).

**Cellular folate, MTX, and purine biosynthesis intermediate levels.** A549 cells were transfected with either control or NAMPT siRNA as described in the NAMPT inhibition section. Three days later, cells were treated with 1000 nM MTX for 24 hour or left untreated. Cells were collected by trypsinization and the resulting pellet was flash frozen in liquid nitrogen or immediately processed and analyzed. Cellular folate and MTX levels were analyzed by ultra-performance liquid chromatography (UPLC) tandem mass spectrometry as described previously (Funk et al., 2013; Funk et al., 2014). Cellular levels of 5-aminoimidazole-4-carboxamide ribonucleotide (ZMP) and inosine 5’-monophosphate (IMP) were measured by an additional UPLC-UV assay. Analytes were extracted from cells treated with control or NAMPT siRNA by re-suspending the cell pellet in 100% acetonitrile followed by vortex mixing for 30 seconds and sonication for 5 minutes. Samples were centrifuged at 21,100 x g for 5 minutes and 10 µL of the resulting supernatant was injected. Sample separation was conducted on a Waters BEH Amide HILIC chromatography column (150 x 3.0mm packed with 1.7 µm particles) using an isocratic method consisting of 33% 27 mM potassium dihydrogen phosphate pH 4.5 (mobile phase A) and 77% acetonitrile (mobile phase B) at a flow rate of 0.9 mL/min. Following each run the column was washed for 2 minutes with a 50/50 mixture of mobile phase A and B. The column was re-equilibrated for 3 minutes under the conditions for isocratic separation prior to the next injection. Ultraviolet absorption was monitored at 248 nm and 262 nm and a 5-point calibration curve ranging from 1 to 100 µM was constructed for each analyte. Concentrations of ZMP and IMP
were determined and normalized based on the average cell count for the samples and expressed in pmoles per million cells.

**NAD and ATP cellular levels.** Total cellular NAD content was measured using a colorimetric enzyme-linked microplate assay (catalog no. 600480, Cayman Chemical Company, Ann Arbor, MI) and total cellular ATP content was measured using firefly luciferase microplate assays (catalog no. 6016943, PerkinElmer, Waltham, MA). Assays were conducted in a 96-well plate format following the manufacturer’s protocol and normalized to total protein.

**Drugs and Reagents.** Resazurin sodium salt (ThermoFisher Scientific, Waltham, MA) was re-suspended in 0.16 mg/mL, pH 7.4 phosphate-buffered saline and passed through a 0.2 µm syringe filter. High performance liquid chromatography purified NAMPT siRNA (sense: 5'-CCACCCCAACACAAGCAAGUUCU-AU-3') and scrambled control siRNA (sense: 5'-CCACCAACAAACGUGAUC-AU-3') were custom synthesized (ThermoFisher Scientific, Waltham, MA). Thymidine (catalog no. CAS 50-89-5, ACROS organics, New Jersey), Hypoxanthine (catalog no. 105451) Folinic Acid (catalogue no. 191504) (MP Biomedicals, Solon, OH), and \( \beta \)-Nicotinamide adenine dinucleotide (catalog no. N1630, Sigma, St. Louis, MO) were dissolved in water at 0.1M concentration. Methotrexate (catalog no. 13960, Cayman Chemical Company, Ann Arbor, MI) was dissolved in 100% DMSO (catalog no. BP231-100, ThermoFisher Scientific, Waltham, MA) at 0.1 M concentration. Olaparib (catalog no. S1060, Selleckchem, Houston, TX 77054 USA) was dissolved in 100% DMSO at 10mg/ml concentration. FK-866 (catalog no. 4808, Tocris Bioscience, Bristol, UK) was dissolved in water at a concentration of 5 mM. External reference standards for ZMP (catalog no. A611705, Toronto Research Chemicals, Toronto, ON) and IMP (catalog no. 226260250, Acros Organics, Morris, NJ) were dissolved in 100% acetonitrile.
Statistical analysis. In all figures, data are shown as mean ± standard deviation. Associations between continuous variables were assessed by simple linear regression with log transformation of non-normally distributed variables. Data were compared by unpaired Student’s t-test analysis and significance was determined at \( P < 0.05 \).

Results

Effect of NAMPT inhibition on MTX activity. Previous work by our group demonstrated that siRNA-based silencing of NAMPT and pharmacological inhibition of NAMPT with FK-866 both result in a significant and similar increase in sensitivity to the growth inhibitory effects of MTX in the A549 human lung carcinoma cell line (Funk et al., 2016). To demonstrate the relevance of inhibition of NAMPT on MTX activity in primary human tissues we employed primary human fibroblasts and peripheral blood mononuclear cells to evaluate the effect of NAMPT inhibition on MTX response. Utilizing the siRNA-based silencing approach in the AG07095 human fibroblast cell line we found that silencing of NAMPT resulted in a significant increase in sensitivity to the growth inhibitory effects of MTX (Figure 1A). Notably, fibroblasts treated with control siRNA failed to demonstrate any measureable level of growth inhibition following a 96 hour treatment with MTX at concentrations up to 10 µM. In contrast, fibroblasts treated with NAMPT siRNA demonstrated ~25% growth inhibition with half maximal response at a mean±SD MTX concentration of 49.1±14.7 nM. Similarly, we found that treatment of isolated PBMCs with 10 nM MTX or 0.1 nM FK-866 individually had no impact on their response to stimulation following treatment with PHA (Figure 1B). However, treatment with MTX in combination with FK-866 resulted in a synergistic inhibition of lymphocyte proliferation and further supports a synergistic relationship whereby variations in NAMPT activity impact response to MTX in a diversity of tissues.
MTX activity in NAMPT deficient cells is folate-dependent. The anti-proliferative activity of MTX is primarily mediated through the competitive inhibition of DHFR resulting in depletion of the intracellular pool of bioactive folates; however folate-independent mechanisms of action have been proposed (Dolezalova et al., 2005; Funk et al., 2013; Sramek et al., 2017). The anti-folate effects of MTX are reversible through supplementation with the reduced and methylated form of folate, folinic acid, also referred to as 5-formyl tetrahydrofolate (Shea et al., 2014; Koh et al., 2016). Therefore, initial studies were performed to confirm that the anti-proliferative activity of MTX in NAMPT-deficient cells was mediated through the anti-folate activity of MTX. Consistent with previous results (Funk et al., 2016), siRNA-based silencing of NAMPT resulted in reduced expression of NAMPT in A549 cells, as demonstrated by western blot (Figure 2A). By densitometry, the NAMPT band was normalized to GAPDH and demonstrated >95% reduction in cellular NAMPT protein (Figure 2B) and was consistent with depletion of NAMPT mRNA as measured by RT-PCR (Figure 2C). Similar to our previous finding, silencing of NAMPT resulted in a greater than three-fold reduction in the concentration of MTX resulting in half-maximal inhibition (IC₅₀) of cell growth at 96-hours (mean±SD: 66.9±12 vs. 18.5±0.3 nM, p<0.005) (Figure 2D). Supplementation of growth media with 10 µM folinic acid was found to completely rescue both control cells and the NAMPT-deficient cells from the anti-proliferative activity of MTX (Figure 2D).

NAD supplementation reverses MTX sensitivity in NAMPT-deficient cells.

Consistent with our previously reported findings, siRNA-based silencing of NAMPT results in a marked reduction (~68%) in cellular NAD levels (Figure 3A) (Funk et al., 2016). Therefore, to verify the role of NAD depletion as the basis for enhanced MTX sensitivity in NAMPT knockdown cells, we measured the effect of NAD supplementation on MTX response in
NAMPT deficient cells (Figure 3B). The addition of 200 \( \mu \text{M} \) NAD in cell culture media caused a 5-fold increase in the IC\(_{50}\) for growth inhibition of MTX in NAMPT deficient cells (mean±SD: 17.92±2.05 vs. 95.6±4.50 nM, \( p=0.00001 \)) that were similar to those observed previously in control cells with normal NAMPT levels. In contrast, supplementation of NAD in control cells with normal NAMPT and NAD levels resulted in no significant effect on MTX response (data not shown).

**NAMPT deficiency does not disrupt folate homeostasis or increase MTX uptake.**

The phosphorylated and reduced form of NAD, NADPH is necessary for proper folding and stability of DHFR and serves as a cofactor in the reduction of dihydrofolate to tetrahydrofolate (THF) (Ainavarapu et al., 2005; Hsieh et al., 2013). As a result, decreases in cellular NADPH would be expected to result in both the reduced expression of DHFR as well as reduced enzymatic activity. Recognizing that inhibition of NAMPT activity results in both the depletion of cellular NAD and NADP(H) pools (Hsieh et al., 2013), it is reasonable to hypothesize that depletion of cellular NADPH secondary to reduced NAMPT activity would increase sensitivity to MTX through a reduction in DHFR expression and activity. To determine the effect of reductions in cellular NAMPT levels on the expression of DHFR, both control and NAMPT deficient cells were evaluated for DHFR expression by western blot (Figure 4A). Densitometry analysis confirmed that reductions in NAMPT expression had no effect on the cellular levels of DHFR (Figure 4B). DHFR activity was assessed by measuring cellular levels of THF and its methylated metabolites 5-methyl-THF and 5,10-methenyl-THF (Figure 4C). Cellular folate levels in the NAMPT deficient cells were not consistent with a reduction in DHFR activity, and actually resulted in an increase in cellular folates levels but were not found to be statistically significant. Further, to evaluate whether the increased sensitivity to MTX potentially resulted
from an increase in the cellular uptake of MTX in the NAMPT deficient cells, concentrations of MTX and its polyglutamated metabolites were measured in control and NAMPT deficient cells (Figure 4D). The NAMPT deficient cells were not found to take up more MTX, but in contrast appeared to have lower levels of the drug and its pharmacologically active metabolites compared to the control cells.

**MTX does not cause synergistic depletion of cellular NAD in NAMPT-deficient cells.** Although the increased sensitivity of NAMPT deficient cells appears to result from a reduction in the enzymatic function of NAMPT causing the cellular depletion of NAD, the biochemical basis for increased MTX activity in NAMPT-deficient cells remains unclear. As discussed in the introduction, a previous study reported that the anti-folate agent pemetrexed promotes the cytotoxicity of a chemical inhibitor of NAMPT through activation of PARP-1 in response to DNA damage by pemetrexed, leading to the synergistic depletion of cellular NAD (Chan et al., 2014). In contrast to this previous work, MTX was not found to cause any measurable activation of PARP-1 as monitored by western blot analysis for the production of PAR (Figure 5A). In agreement with these findings, treatment with MTX did not cause any significant DNA damage as measured by DNA gel electrophoresis (Figure 5B). Finally, although MTX caused a slight but insignificant reduction in cellular NAD levels in control cells, MTX failed to cause any further depletion of NAD levels in the NAMPT-deficient cells (Figure 5C).

Furthermore, to rule out involvement of PARP-1 activation by MTX as the mechanism of increased response to MTX, the anti-proliferative activity of MTX was measured in the presence of the PARP inhibitor olaparib, which was previously demonstrated to rescue pemetrexed toxicity in cells treated with a NAMPT inhibitor (Chan et al., 2014). We did not find any
significant change in the growth inhibition of MTX in NAMPT-deficient or control cells in the presence of olaparib (Figure 6).

**Increased MTX activity occurs through synergistic depletion of cellular ATP.** As an anti-folate, MTX is a potent inhibitor of folate-dependent enzymes responsible for *de novo* purine and pyrimidine biosynthesis (Fairbanks et al., 1999; Budzik et al., 2000; Kremer, 2004). As a result, MTX causes the exposure-dependent depletion of the intracellular nucleotide pool, including the depletion of intracellular ATP (Budzik et al., 2000; Chan et al., 2014). Pharmacological inhibition of NAMPT also ultimately causes the depletion of intracellular ATP, secondary to the depletion of cellular NAD, and has been directly associated with cytotoxicity (Tan et al., 2013; Moore et al., 2015). Therefore, we investigated whether the increased anti-proliferative effect of MTX in NAMPT-deficient cells is associated with synergistic depletion of the cellular ATP pool. Cellular ATP levels in control and NAMPT-deficient cells were measured, and interestingly, NAMPT-deficient cells had significantly higher levels of ATP compared to control cells (Figure 7A). Increase in cellular ATP content in response to NAMPT inhibition is previously reported in cells which solely rely on salvage or nicotinamide pathway for NAD synthesis (Tolstikov et al., 2014). Treatment with MTX over 96 hours resulted in the dose-dependent depletion of cellular ATP in both control and NAMPT-deficient cells (Figure 7B). However, the NAMPT-deficient cells were found to be significantly more sensitive to the ATP depleting activity of MTX. Similar to the enhanced anti-proliferative effects seen with NAMPT-deficiency, reduced NAMPT expression was found to result in a nearly four-fold reduction in the concentration of MTX resulting in half-maximal depletion of cellular ATP (mean±SD: 15.01±3.63 vs. 3.93±0.35 nM, p<0.005).
An analysis of the intermediates of the *de novo* purine synthesis pathway was undertaken to evaluate whether NAMPT deficiency impacts the activity of aminimidazole carboxamide ribonucleotide transformylase (AICART), which is one of the primary intracellular targets of MTX in the inhibition of *de novo* purine biosynthesis (Allegra et al., 1985). To evaluate AICART activity we measured both the substrate, ZMP, and the product, IMP, of AICART in NAMPT-deficient and control cells (Figure 8). Interestingly, intracellular levels of both ZMP and IMP were found to be significantly elevated in NAMPT-deficient cells. However, a comparison of the ratio of IMP:ZMP as a static measure of AICART enzymatic activity revealed no significant difference between the NAMPT-deficient and control cells.

Supplementation with intermediates of purine and pyrimidine biosynthesis can restore cellular nucleotide pools depleted in response to treatment with MTX (Piper et al., 1983; Chan and Howell, 1990). Therefore, to investigate whether depletion of nucleotide precursors by MTX is responsible for the increase in pharmacological activity observed in response to NAMPT inhibition, we evaluated cell viability, NAD levels, and ATP levels in control and NAMPT deficient cells treated with MTX, with and without supplemental hypoxanthine (HYP) and thymidine (THY) (Figure 9). Under the conditions tested, supplementation with HYP and THY completely rescued the anti-proliferative effects of MTX in both control and NAMPT knockdown cells (Figure 9A). The observed increase in cell viability corresponded to a marked increase in cellular ATP levels in both the control and NAMPT knockdown cells (Figure 9B). However, the reversal in the anti-proliferative activity of MTX with HYP-THY supplementation had no effect on NAD levels in the NAMPT-deficient cells (Figure 9C).
Discussion

Based on the results of this study we conclude that reductions in the enzymatic activity of NAMPT increase the sensitivity of cells to the inhibition of nucleotide biosynthesis by MTX and potentiate the MTX-mediated depletion of cellular ATP. Together, these findings illustrate a novel mechanism through which disruption of cellular NAD metabolism, through reduction in the enzymatic activity of NAMPT, enhances the pharmacological activity of the anti-folate therapeutic MTX. These findings suggest that variation in NAMPT expression and NAD homeostasis, reflecting both potential genetic and environmental factors, may impact the sensitivity of patients to the pharmacological effects of MTX, and is supported by our previous clinical findings (Funk et al., 2016).

Our initial experiments sought to demonstrate the interaction of NAMPT and MTX in primary tissues and to determine whether the enhanced sensitivity to MTX observed with NAMPT-deficient cells was mediated through the anti-folate activity of MTX. We found that inhibition of NAMPT activity potentiated the growth inhibitory effects of MTX in both primary human fibroblasts and isolated lymphocytes (Figure 1), and therefore demonstrated that this interaction is broadly applicable to both transformed and primary tissues. Although MTX is widely believed to mediate its pharmacological activity through inhibition of folate-dependent biochemical pathways, either through the depletion of the intracellular pool of bioactive folates or through the direct inhibition of the various folate-dependent enzymes, some investigators have suggested folate-independent pharmacological effects of MTX mediated through inhibition of JAK-STAT signaling, induction of oxidative stress, and mitochondrial toxicity (Phillips et al., 2003; Thomas et al., 2015; Al Maruf et al., 2017; Zimmerman et al., 2017). Therefore, we evaluated whether supplementation with folinic acid would reverse the increased anti-
proliferative effects of MTX in NAMPT-deficient cells (Figure 2). Our finding that folinic acid supplementation completely rescues the NAMPT-deficient cells from the anti-proliferative effects of MTX suggests that the enhanced sensitivity of cells with reduced NAMPT activity is a result of increased sensitivity to the anti-folate effects of MTX and isn’t mediated through a secondary folate-independent pharmacological mechanism. Similarly, recognizing that much debate continues on the biological function of NAMPT, beyond its role as the rate-limiting enzyme in NAD biosynthesis (Revollo et al., 2004; Rongvaux et al., 2008; Moore et al., 2015; Chen et al., 2016), we sought to determine whether the depletion of cellular NAD in NAMPT-deficient cells was responsible for the observed increase in sensitivity to the anti-proliferative activity of MTX. Therefore, the effect of NAD supplementation on the anti-proliferative effect of MTX was measured in NAMPT-deficient cells (Figure 3). Our finding that NAD supplementation of NAMPT-deficient cells reversed the observed increase in sensitivity to the anti-proliferative effects of MTX established that reductions in the enzymatic activity of NAMPT was responsible for the increased sensitivity towards MTX, and that the effect wasn’t a manifestation of one of the multitude or purported non-enzymatic functions of NAMPT. Together, this data established that reduced cellular concentrations of NAD, resulting from deficiency in the enzymatic activity of NAMPT, increases the sensitivity of cells to the anti-folate mediated anti-proliferative effects of MTX. Further, this data supports a mechanistic interaction through which regulation of cellular NAD can impact the sensitivity of cells to the pharmacological activity of anti-folate therapeutics.

Recognizing that a multitude of mechanisms exist through which cells can display enhanced or diminished sensitivity to MTX (Cutolo et al., 2001; Kremer, 2004), we sought to understand the mechanism through which reductions in cellular NAD increases the sensitivity of
cells to the anti-folate effects of MTX. Among the most obvious potential mechanisms would be reductions in DHFR expression or activity, as has been previously demonstrated as an important factor impacting the sensitivity of cells to the pharmacological activity of MTX (Cutolo et al., 2001; Hsieh et al., 2013). Recognizing that NADPH is depleted through inhibition of NAMPT and the NADPH is required for the enzymatic activity and stabilization of DHFR, we sought to evaluate the effect of reduced NAMPT activity on DHFR (Hsieh et al., 2013). However, we failed to find a change in DHFR protein levels in NAMPT-deficient cells (Figure 4). We also found no significant change in the intracellular concentrations of the major bioactive forms of folate in NAMPT-deficient cells (Figure 4). Therefore, neither the expression nor the activity of DHFR was not found to play a role in the observed increase in sensitivity to MTX in NAMPT-deficient cells.

From a pharmacological standpoint the other major mechanism that has been commonly associated with differences in the sensitivity to MTX are differences in the cellular uptake and polyglutamation of MTX (Tian and Cronstein, 2007; Funk et al., 2013; Funk et al., 2014). As a result we measured the cellular levels of MTX and its polyglutamated metabolites in NAMPT-deficient cells and found no significant difference, as compared to control cells (Figure 4). Therefore, our data suggests that the increased sensitivity to MTX in the NAMPT-deficient cells isn’t a product of either a dysregulation of intracellular folates or a change in the cellular disposition of MTX. Rather, these findings suggest the increased sensitivity of NAMPT-deficient cells must occur through a mechanism that is downstream from regulation of MTX disposition and folate homeostasis.

Although depletion of cellular NAD isn’t a commonly reported effect of MTX therapy, the previous report that the anti-folate pemetrexed potentiated the cytotoxic effects of GMX1777
through the synergistic depletion of cellular NAD led us to evaluate the effect of MTX on NAD levels in our NAMPT-deficient cells (Chan et al., 2014). In our evaluations we found that MTX had no effect on cellular NAD in NAMPT-deficient cells, and only a modest effect in control cells (Figures 5 and 9). To further confirm these findings we evaluated NAMPT-deficient cells for evidence of direct DNA damage, the activation of PARP-1, and the effect of the PARP-1 inhibition on the anti-proliferative activity of MTX. We found no evidence of MTX mediated DNA damage, PARP-1 activation, or reversal of MTX activity by inhibition of PARP-1 (Figures 5 and 6). In addition, when control cells were supplemented with NAD there wasn’t an effect on the anti-proliferative activity of MTX, which further suggests that under normal conditions MTX doesn’t mediate its anti-proliferative activity through depletion of NAD. These findings suggest that the increased anti-proliferative activity of MTX in NAMPT-deficient cells does not result from the synergistic depletion of NAD through activation of PARP-1, as was previously demonstrated for the interaction between pemetrexed and GMX1777 (Chan et al., 2014).

The anti-proliferative activity of MTX is primarily associated with the inhibition of *de novo* purine and pyrimidine biosynthesis mediated through the inhibition of phosphoribosylglycinamidase formyltransferase (GART) and AICART in the purine biosynthesis pathway and thymidylate synthase (TS) in the pyrimidine biosynthesis pathway (Allegra et al., 1985; Baram et al., 1988; Sant et al., 1992). Inhibition of nucleotide biosynthesis by MTX has been found to result in the depletion of cellular ATP at physiologic relevant MTX concentrations, and to be associated with its antiproliferative activity (Smolenska et al., 1999; Chan et al., 2014). Therefore, we sought to evaluate cellular levels of ATP in response to MTX treatment in NAMPT-deficient cells and found these cells to be approximately four-fold more sensitive to the ATP-depleting effects of MTX compared to control cells (Figure 7).
Interestingly, the fold variation in the ATP-depleting activity and the anti-proliferative activity were similar between NAMPT-deficient and control cells, and suggests a relationship between the increased sensitivity of NAMPT-deficient cells to the depletion of ATP by MTX and the anti-proliferative activity of MTX. To investigate the possibility that NAMPT-deficient cells had altered AICART activity we measured intracellular concentrations of ZMP and IMP, and calculated the IMP:ZMP ratio (Figure 8). We found no difference in AICART activity in NAMPT-deficient and control cells. However, we did find that NAMPT deficient cells had higher intracellular concentrations of both ZMP and IMP and indicated an increase in de novo purine biosynthesis in NAMPT-deficient cells that could foreseeably make them more vulnerable to the growth inhibitory effects of MTX mediated through the inhibition of purine biosynthesis. Further, to verify the role of inhibition of nucleotide biosynthesis as the mechanism for the increased anti-proliferative activity of MTX, we supplemented NAMPT-deficient cells with intermediates of the nucleotide salvage pathway (Figure 9). Supplementation of HYP-THY completely prevented the depletion of ATP in the NAMPT-deficient cells and was associated with inhibition of the anti-proliferative effects of MTX. Further, cellular NAD levels were not found to be affected by supplementation with HYP-THY. Together, these results demonstrate that the NAMPT-deficient cells appear to have an increase in demand for de novo purine biosynthesis and are therefore more sensitive to the inhibition of nucleotide biosynthesis by MTX resulting in enhanced depletion of the intracellular ATP pool.

In conclusion, our findings establish a new functional link between anti-folate pharmacology and regulation of cellular NAD by NAMPT and suggest the potential importance of variation in NAMPT activity in the observed variation in clinical response to MTX. An understanding of the regulation of intracellular NAD homeostasis may represent an important
factor impacting the pharmacological activity of MTX. Further study is needed to evaluate how this information can be potentially used to improve response to MTX therapy in the treatment of autoimmune arthritis.
Authorship Contributions

*Participated in research design:* Singh, Funk, Leeder, and Becker

*Conducted experiments:* Singh, Funk

*Contributed new reagents or analytic tools:* van Haandel, Funk, Heruth, and Ye

*Performed data analysis:* Singh and Funk

*Wrote or contributed to the writing of the manuscript:* Singh and Funk
References


Conflict of Interest

The authors report no financial conflicts of interest with regard to the work presented in this manuscript.
Figure Legends.

**Figure 1. Inhibition of NAMPT sensitizes primary human tissue to the growth inhibitory effects of MTX.** Primary human fibroblasts were transfected with either control scrambled siRNA or with NAMPT-specific siRNA. Twenty-four hours post transfection, cells were treated with MTX at concentrations up to 10 µM for 96 hours (A). Isolated human lymphocytes were left unstimulated or stimulated with 2% phytohemagglutinin (PHA) and treated with either 10 nM MTX alone, 0.1 nM FK-866 alone, or 10 nM MTX in combination with 0.1 nM FK-866 (B). Cell viability was measured by fluorescence spectroscopy using the resazurin reduction assay. Experiments were conducted in triplicate and the resulting mean±SD for each experiment is presented. Statistical testing was conducted using the Student’s t-test analysis.

**Figure 2. MTX activity in NAMPT deficient cells is folate-dependent.** A549 cells were transfected with either control scrambled siRNA or with siRNA directed towards NAMPT. Twenty-four hour post transfection, cells were treated with different concentrations of MTX alone or in combination with 10 µM folinic acid for 96 hours. Knockdown of NAMPT by siRNA was confirmed by western blot (A), quantified by densitometry analysis (B), and verified by RT-PCR (C). Cell viability was measured by fluorescence spectroscopy using the resazurin reduction assay. Effect of MTX toxicity alone or in combination with 10 µM folinic acid was determined as percent viability based on untreated control cells (D). Experiments were conducted in triplicate and the resulting mean±SD for each experiment is presented. Concentrations of MTX required for half maximal inhibition of 50% inhibition of cell viability were determined and compared by Student’s t-test analysis.
Figure 3. NAD supplementation reverses enhanced MTX sensitivity in NAMPT-deficient cells. A549 cells were transfected with either control scrambled siRNA or with siRNA directed towards NAMPT and cellular NAD levels were measured 96 hours post transfection (A). Cellular viability was measured in NAMPT-deficient cells and treated with various concentrations of MTX with or without supplementation of 200 μM NAD (B). Experiments were conducted in triplicate and the resulting mean±SD for each experiment is presented. NAD levels were compared by Student t-test analysis. Concentrations of MTX required for half maximal inhibition of 50% inhibition of cell viability were determined and compared by Student’s t-test analysis.

Figure 4. Inhibition of NAMPT does not affect DHFR expression or intracellular levels of folate or MTX. A549 cells were transfected with either control scrambled siRNA or with siRNA directed towards NAMPT and protein levels of DHFR were monitored 96 hours post transfection (A). For densitometry analysis, DHFR protein levels were normalized to GAPDH (B). Cellular concentrations of folate (C) and MTX levels (D) were analyzed in control and NAMPT deficient cells treated for 24 h with 1000 nM MTX. Experiments were conducted in triplicate and the resulting mean±SD for each experiment is presented and were compared by Student’s t-test analysis.

Figure 5. MTX does not cause synergistic depletion of cellular NAD in NAMPT-deficient cells. A549 cells were transfected with either control scrambled siRNA or with siRNA directed towards NAMPT and 24 h post transfection, cells were treated with 1000 nM MTX for 96 h or 50 mM Etoposide for 24 h to determine activation of PARP by measuring PAR formation by western blot (A). Control and NAMPT-deficient cells were treated with different concentrations of MTX for 96 h and total DNA was separated on 1% agarose gel to evaluate DNA damage (B).
Total NAD levels were monitored in control and NAMPT-deficient cells treated with different concentrations of MTX for 96 hours (C). Experiments were conducted in triplicate and the resulting mean±SD for each experiment is presented and were compared by Student’s t-test analysis.

**Figure 6. Increased MTX activity does not occur through activation of PARP.** A549 cells transfected with either control scrambled siRNA or with siRNA directed towards NAMPT were treated with different concentrations of MTX with or without 10 μM olaparib. The effect of inhibition of PARP-1 by olaparib on MTX toxicity in control (A) and NAMPT-deficient (B) cells was determined by normalizing cell growth inhibition with MTX against control cells. Experiments were conducted in triplicate and the resulting mean±SD for each experiment is presented. Concentrations of MTX required for half maximal inhibition of 50% inhibition of cell viability were determined and compared by Student’s t-test analysis.

**Figure 7. NAMPT inhibition results in the synergistic depletion of cellular ATP by MTX.** A549 cells transfected with either control scrambled siRNA or with siRNA directed towards NAMPT were treated with different concentrations of MTX and cellular ATP levels were measured 96 h post-transfection (A) and in response to treatment with different concentrations of MTX over 96 hours (B). The effect of MTX on cellular ATP was determined by normalizing cellular ATP levels to the untreated control cells. Experiments were conducted in triplicate and the resulting mean±SD for each experiment is presented and was compared by Student’s t-test analysis.
Figure 8. **NAMPT inhibition doesn’t affect AICART activity, but is associated with an increase in intracellular intermediates of de novo purine biosynthesis.** A549 cells were transfected with either control scrambled siRNA or with NAMPT-specific siRNA. Following 72 hours under normal culture conditions cells were subsequently harvested and intracellular concentrations of ZMP (A), IMP (B), and the ratio of IMP:ZMP (C) were determined. Experiments were conducted in triplicate and the resulting mean±SD for each experiment is presented and were compared by Student’s t-test analysis.

Figure 9. **Supplementation of nucleotide biosynthesis rescues cell viability and ATP levels, but not NAD levels.** A549 cells transfected with either control scrambled siRNA or with siRNA directed towards NAMPT were treated with 1000 nM of MTX alone or together with a combination of 100 µM of hypoxanthine and 100 µM thymidine for 96 hours and measured for cellular viability (A), cellular NAD levels (B), and cellular ATP levels (C). Experiments were conducted in triplicate and the resulting mean±SD for each experiment is presented and were compared by Student’s t-test analysis.
Figure 1

A

B

% Viability

Methotrexate (nM)

Unstimulated

Control

MTX

FK-506

MTX + FK-506

p<0.0001

p<0.0001

p<0.001

p<0.001
Figure 2

A

NAMPT siRNA  Scr siRNA

75
50
37
25

MW

NAMPT
GAPDH

B

$\rho < 0.001$

C

Relative mRNA expression

$\rho < 0.0005$

D

Relative protein expression

E

% Viability

F

Methotrexate (nM)
Figure 4

A

NAMPT siRNA
Scrn siRNA

NAMPT
DHFR
GAPDH

B

Relative protein expression

NS

Scrn siRNA
NAMPT siRNA

C

[fold]_calc (ng/mg protein)

5m-THF
THF
5,10-MeTHF

D

[MTX-PG]_calc (ng/mg protein)

MTX-PG1
MTX-PG1
MTX-PG1
MTX-PG1
MTX-PG1

Downloaded from Jpet.aspetjournals.org at ASPET Journals on February 11, 2021
Figure 5

A

MTX (1000 nM) DMSO

NAMPT-siRNA Scr-siRNA NAMPT-siRNA Scr-siRNA

PAR

250 200 150 100 50 0

250 200 150 100 50 0

GAPDH

C

Scr siRNA

NS

NS

NAMPT siRNA

NS

NS

NAD (pmol/mg of protein)

MTX

Control 10 nM 100 nM 1000 nM

NAD (pmol/mg of protein)

MTX

Control 10 nM 100 nM 1000 nM
Figure 6

A

B

\[ \text{Percentage Viability vs. Methotrexate (nM)} \]

\[ \text{Percentage Viability vs. Methotrexate (nM)} \]
Figure 7

A

![Bar graph showing ATP levels](image)

B

![Graph showing ATP levels](image)
Figure 8

A

B

C

NAMPT siRNA

Scr siRNA

IMP (mol/ml x 10^6 cells)

IMP (mol/ml x 10^6 cells)

IMP-2MP Ratio

ZMP (nmol/ml x 10^6 cells)

p<0.05

p<0.001

NS

NAMPT siRNA

Scr siRNA

0.00

0.05

0.10

0.15

0.20

0.25

0.30

Journal of Pharmacology and Experimental Therapeutics
Figure 9

(A) % Viability

(B) NAD (% of control)

(C) ATP (% of control)